The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure

American Heart Journal

Volumn 142, Issue 2, 2001, Pages 340-349

  Schalcher, Christoph ^a   Cotter, Gadi ^d   Reisin, Leonardo ^e   Bertel, Osmund ^b   Kobrin, Isaac ^c   Guyene, Than Tam ^f   Kiowski, Wolfgang ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Stadspital Triemli   (Switzerland)

^c ACTELION PHARMACEUTICALS LTD   (Switzerland)

^d ASSAF HAROFEH MEDICAL CENTER   (Israel)

^e Barzilai Hospital   (Israel)

^f INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; PLACEBO; TEZOSENTAN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; HEART CATHETERIZATION; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RIGHT ATRIUM PRESSURE; HEMODYNAMICS; HUMAN; LUNG ARTERY PRESSURE; LUNG CAPILLARY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; MULTICENTER STUDY; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC VASCULAR RESISTANCE;

EID: 0034895218     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2001.116760     Document Type: Article

References (41)

1. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
2. Role of endothelin in the exercise intolerance of chronic heart failure
3. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure
4. Increased endothelin in experimental heart failure
5. Endothelin in chronic heart failure: Current position and future prospects
6. Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension
7. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction
8. Molecular characterization of endothelin receptors
9. Endothelin-1 modulates vascular smooth muscle structure and vasomotion: Implications in cardiovascular pathology
10. B receptors mediate vascular smooth muscle contraction
11. Molecular cloning of a non-isopeptide-selective human endothelin receptor
12. Endothelin-1 and endothelin-3 release EDRF from isolated perfused arterial vessels of rat and rabbit
13. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor
14. Autocrine role for the endothelin-B receptor in the secretion of adrenomedullin
15. Endothelin receptors in cultured adult rat cardiac fibroblasts
16. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure
17. Evidence for endothelin-1 -mediated vasoconstriction in severe chronic heart failure
18. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure
19. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure
20. Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use
21. On-line sample processing and analysis of diol compounds in biological fluids
22. Impact of medical therapy on pulmonary hypertension in patients with congestive heart failure awaiting cardiac transplantation
23. Results of long-term vasodilator therapy in patients with refractory congestive heart failure
24. The acute haemodynamic effects of quinapril, a new non-sulfhydryl angiotensin converting enzyme inhibitor, in patients with severe congestive cardiac failure
25. Enalapril: A new angiotensin-converting enzyme inhibitor in chronic heart failure: Acute and chronic hemodynamic evaluations
26. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure
27. Pulmonary artery pressure measurement: State of the art
28. Arterial baroreflex abnormalities in heart failure: Reversal after orthotopic cardiac transplantation
29. Naloxone augments sympathetic outflow induced by centrally administered endothelin in conscious rabbits
30. Distribution and functional significance of the endothelin receptor subtypes in the rat adrenal gland
31. Characterization of endothelin-1 stimulation of catecholamine release from adrenal chromaffin cells
32. Role of endogenous endothelin in chronic heart failure: Effect of a long-term treatment with an endothelin antagonist on survival, hemodynamic and cardiac remodeling
33. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure
34. Plasma norepinephrine in congestive heart failure
35. Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure
36. Endothelin in human congestive heart failure
37. Results of a randomized, placebo-controlled, hemodynamic trial with an intravenous endothelin-1 receptor antagonist in patients with congestive heart failure
38. Heart Failure Society of America (HFSA) practice guidelines: HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction-pharmacological approaches
39. Heart failure: Evaluation and treatment of patients with left ventricular systolic dysfunction
40. Inotropic therapy for heart failure
41. Newer drug therapy for congestive heart failure